Novel Microdevices, an early-stage company structured around development of new types of point-of-care diagnostics that are affordable, portable, reliable, quick, and simple to use tests inthe arenas of sexually transmitted diseases and other pathogens. The firm is using advanced microfluidics to develop a hand-held diagnostic device for point-of-care (POC) molecular testing. In the Spring 2021 it was announced that Novel Microdevices, Inc. had been awarded up to $13.8 million from CARB-X for the development of a rapid, point-of-care, molecular diagnostic platform for the detection of sexually transmitted diseases, including antibiotic-resistant infections
